{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:26:18Z","timestamp":1761513978047},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients\u2019 health-related quality of life (HRQoL) in clinical studies. HRQoL\/functioning and symptoms of patients with relapsed\/refractory MM (RRMM) receiving second- or third-line lenalidomide or bortezomib treatment were measured in a prospective European multicentre, observational study at different time points. At baseline, patients in the lenalidomide cohort were frailer than in the bortezomib cohort with more rapid disease progression at study entry (more patients with Eastern Cooperative Oncology Group performance status &gt;2, shorter time from diagnosis, more chronic heart failure, higher serum creatinine levels, more patients with dialysis required). About 40% of the patients receiving lenalidomide discontinued the study in &lt;6 months while 55% in the bortezomib cohort discontinued. No substantial HRQoL deterioration was observed for the first 6 months in patients with RRMM receiving one or the other treatment. For patients still on treatment at study completion (month 6), only the European Organization for Research and Treatment of Cancer Quality-of-Life Core domains of Diarrhoea and Global Health Status\/QoL had worsened in the lenalidomide and bortezomib cohorts, respectively. A clinically meaningful deterioration in HRQoL was more often observed for patients who discontinued the study prior to 6 months in the bortezomib cohort than in the lenalidomide cohort.<\/jats:p>","DOI":"10.1038\/bcj.2017.20","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T14:20:39Z","timestamp":1489760439000},"page":"e543-e543","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prospective longitudinal study on quality of life in relapsed\/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment"],"prefix":"10.1038","volume":"7","author":[{"given":"X","family":"Leleu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Vande Broek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Gilet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Arnould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M T","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"BFbcj201720_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046\u20131060.","journal-title":"N Engl J Med"},{"key":"BFbcj201720_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1586\/erm.11.44","volume":"11","author":"SY Kristinsson","year":"2011","unstructured":"Kristinsson SY, Minter AR, Korde N, Tan E, Landgren O . Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn 2011; 11: 593\u2013603.","journal-title":"Expert Rev Mol Diagn"},{"key":"BFbcj201720_CR3","volume-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer: Lyon, France, 2013. [cited 11 September 2015]; available from http:\/\/globocan.iarc.fr."},{"key":"BFbcj201720_CR4","unstructured":"NCI (National Cancer Institute). Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Fact Sheets: Myeloma. [cited 11 September 2015]; available from http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"BFbcj201720_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/asheducation-2010.1.303","volume":"2010","author":"S Lonial","year":"2010","unstructured":"Lonial S . Relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program 2010; 2010: 303\u2013309.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbcj201720_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.csbj.2014.05.005","volume":"10","author":"I Spicka","year":"2014","unstructured":"Spicka I . Advances in multiple myeloma therapy during two past decades. Comput Struct Biotechnol J 2014; 10: 38\u201340.","journal-title":"Comput Struct Biotechnol J"},{"key":"BFbcj201720_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph8010001","volume":"8","author":"NM Merin","year":"2014","unstructured":"Merin NM, Kelly KR . Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals (Basel) 2014; 8: 1\u201320.","journal-title":"Pharmaceuticals (Basel)"},{"key":"BFbcj201720_CR8","first-page":"4","volume":"6","author":"A Poh","year":"2016","unstructured":"Poh A . Multiple myeloma gets three new drugs. Cancer Discov 2016; 6: 4.","journal-title":"Cancer Discov"},{"key":"BFbcj201720_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CMAR.S81310","volume":"7","author":"N Ghosh","year":"2015","unstructured":"Ghosh N, Grunwald MR, Fasan O, Bhutani M . Expanding role of lenalidomide in hematologic malignancies. Cancer Manag Res 2015; 7: 105\u2013119.","journal-title":"Cancer Manag Res"},{"key":"BFbcj201720_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/sj.leu.2405016","volume":"22","author":"KC Anderson","year":"2008","unstructured":"Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008; 22: 231\u2013239.","journal-title":"Leukemia"},{"key":"BFbcj201720_CR11","unstructured":"US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological HealthGuidance for industry. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009. Available at https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf."},{"key":"BFbcj201720_CR12","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/JCO.2012.42.5967","volume":"30","author":"E Basch","year":"2012","unstructured":"Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012; 30: 4249\u20134255.","journal-title":"J Clin Oncol"},{"key":"BFbcj201720_CR13","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123\u20132132.","journal-title":"N Engl J Med"},{"key":"BFbcj201720_CR14","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487\u20132498.","journal-title":"N Engl J Med"},{"key":"BFbcj201720_CR15","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366: 1759\u20131769.","journal-title":"N Engl J Med"},{"key":"BFbcj201720_CR16","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133\u20132142.","journal-title":"N Engl J Med"},{"key":"BFbcj201720_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906\u2013917.","journal-title":"N Engl J Med"},{"key":"BFbcj201720_CR18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3324\/haematol.2015.127860","volume":"100","author":"AK Kvam","year":"2015","unstructured":"Kvam AK, Waage A . Health-related quality of life in patients with multiple myeloma\u2013does it matter? Haematologica 2015; 100: 704\u2013705.","journal-title":"Haematologica"},{"key":"BFbcj201720_CR19","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/leu.2013.185","volume":"27","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Verelst SG, Lewis P, Gray-Schopfer V, Hutchings A, Nixon A et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia 2013; 27: 1959\u20131969.","journal-title":"Leukemia"},{"key":"BFbcj201720_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365\u2013376.","journal-title":"J Natl Cancer Inst"},{"key":"BFbcj201720_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/BF00451727","volume":"3","author":"D Osoba","year":"1994","unstructured":"Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J . Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353\u2013364.","journal-title":"Qual Life Res"},{"key":"BFbcj201720_CR22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007; 43: 1670\u20131678.","journal-title":"Eur J Cancer"},{"key":"BFbcj201720_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2141.1999.01206.x","volume":"104","author":"ML Stead","year":"1999","unstructured":"Stead ML, Brown JM, Velikova G, Kaasa S, Wisloff F, Child JA et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol 1999; 104: 605\u2013611.","journal-title":"Br J Haematol"},{"key":"BFbcj201720_CR24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","volume":"41","author":"TJ Postma","year":"2005","unstructured":"Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005; 41: 1135\u20131139.","journal-title":"Eur J Cancer"},{"key":"BFbcj201720_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH . Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407\u2013415.","journal-title":"Control Clin Trials"},{"key":"BFbcj201720_CR26","first-page":"582","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW . Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582\u2013592.","journal-title":"Med Care"},{"key":"BFbcj201720_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00277-013-1828-8","volume":"93","author":"L Pantani","year":"2014","unstructured":"Pantani L, Zamagni E, Zannetti BA, Pezzi A, Tacchetti P, Brioli A et al. Bortezomib and dexamethasone as salvage therapy in patients with relapsed\/refractory multiple myeloma: analysis of long-term clinical outcomes. Ann Hematol 2014; 93: 123\u2013128.","journal-title":"Ann Hematol"},{"key":"BFbcj201720_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/PPA.S38142","volume":"8","author":"MT Petrucci","year":"2014","unstructured":"Petrucci MT, Finsinger P, Chisini M, Gentilini F . Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits. Patient Prefer Adherence 2014; 8: 939\u2013946.","journal-title":"Patient Prefer Adherence"},{"key":"BFbcj201720_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-8-79","volume":"8","author":"AK Kvam","year":"2010","unstructured":"Kvam AK, Wisloff F, Fayers PM, Gentilini F . Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma. Health Qual Life Outcomes 2010; 8: 79.","journal-title":"Health Qual Life Outcomes"},{"key":"BFbcj201720_CR30","unstructured":"European Medicines Agency - Committee for Medicinal Products for Human Use (CHMP). Revlimid - Summary of opinion EMA\/CHMP\/91664\/2015 Rev 1 issued on 18 February 2015. [cited 24 June 2016]; Available from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/000717\/WC500179310.pdf."},{"key":"BFbcj201720_CR31","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014; 371: 906\u2013917.","journal-title":"N Engl J Med"},{"key":"BFbcj201720_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1600-0609.2012.01788.x","volume":"89","author":"M Delforge","year":"2012","unstructured":"Delforge M, Dhawan R, Robinson Jr D, Meunier J, Regnault A, Esseltine DL et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol 2012; 89: 16\u201327.","journal-title":"Eur J Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201720.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201720","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201720.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:25:41Z","timestamp":1671729941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3]]}},"alternative-id":["BFbcj201720"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2017.20","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,17]]},"assertion":[{"value":"18 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PM, XL, CK, IVB and MTP were Consultant\/Advisor for Celgene and received honoraria from Celgene. XL also received honoraria and travel support from Janssen, Takeda, BMS, Novartis, Amgen, Leopharma and Sanofi. PB and PL declare employment and equity ownership in Celgene. During the course of study and manuscript development, PL was an employee of Celgene. HG, former employee of Mapi, and BA, employee of Mapi, were Consultant\/Advisor for Celgene and received research funding from Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}